Trial
NCT04267913
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
Phase IIWITHDRAWNSAFETYConfidence: HIGH
Sponsor
SWOG Cancer Research Network
Collaborators
National Cancer Institute (NCI)
Condition
Lung Squamous Cell Carcinoma
Intervention
Dexamethasone
Why stopped
The pharmaceutical company sold the compound and pulled out.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-20